THE EFFECT OF SUBCLINIC THYROID PATHOLOGIES ON ERYTHROPOIETINE DOSE IN HEMODIALYSIS PATIENTS.

Engin OnanMehmet YasarBusra SoysalSaime Paydas

Published in: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy (2022)

The erythropoietin dose required to achieve similar hemoglobin levels in hemodialysis patients was significantly higher in subclinical hypothyroid patients than in euthyroid patients. This article is protected by copyright. All rights reserved.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
patient reported